Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Tedisamil has favorable profile as myocardial antiischemic agent

Feb. 25, 1998

No Comments

Abbott will market Orion's calcium sensitizer levosimendan

Feb. 24, 1998

No Comments

Icos monoclonal antibody enters phase II for hemorrhagic shock

Feb. 19, 1998

No Comments

New once-daily antihypertensive combination available in U.S.

Feb. 18, 1998

No Comments

A novel NOS inhibitor possibly involved in elevating arterial pressure

Feb. 18, 1998

No Comments

rAAV vector to be evaluated for cardiovascular gene transfer

Feb. 17, 1998

No Comments

KR-30450 exerts cardioprotective effects in ischemic rat hearts

Feb. 16, 1998

No Comments

Successful results contribute to early termination of phase IIa study of TBC-11251

Feb. 13, 1998

No Comments

Icos reveals new cGMP-specific PDE inhibitors

Feb. 12, 1998

No Comments

Antibradycardic M2 receptor antagonists prepared at Yamanouchi

Feb. 11, 1998

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Cardiovascular
RSS

Tedisamil has favorable profile as myocardial antiischemic agent

Abbott will market Orion's calcium sensitizer levosimendan

Icos monoclonal antibody enters phase II for hemorrhagic shock

New once-daily antihypertensive combination available in U.S.

A novel NOS inhibitor possibly involved in elevating arterial pressure

rAAV vector to be evaluated for cardiovascular gene transfer

KR-30450 exerts cardioprotective effects in ischemic rat hearts

Successful results contribute to early termination of phase IIa study of TBC-11251

Icos reveals new cGMP-specific PDE inhibitors

Antibradycardic M2 receptor antagonists prepared at Yamanouchi

Today's news in brief

Today's news in brief

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

Proteomics study explores how protein changes influence disease

Abbvie and Simcere enter a $1B T-cell engager deal

Cardiovascular RSS

Cardiovascular
RSS